UBS Investment Bank listed Boston Scientific (NYSE:BSX) among its 21 most compelling stock investment selections for 2021.
Marlborough, Mass.-based Boston Scientific was the only medical device company on a list that featured companies such as Amazon, Morgan Stanley and Southwest Airlines. Additionally, Vertex Pharmaceuticals represented the biotech space, while Acadia Healthcare registered for healthcare facilities.
UBS thinks Boston Scientific will continue to post strong growth, even in a post-COVID-19 pandemic environment, thanks to growth drivers including its disposable scopes, according to the report.
Additionally, the company is expected to have less drag from its slower-growing drug-eluting stents and CRM, while its Watchman left atrial appendage closure device and Acurate Neo2 replacement heart valve could contribute more going forward.
UBS sees Boston Scientific as a “top-tier medtech grower” with additional room for expansion, even with recent challenges such as the retiring of its Lotus transcatheter aortic valve replacement (TAVR) device.